Multimedia Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drug

KYBELLA(TM) (deoxycholic acid) Injection Significantly Improves Submental Fullness, or "Double Chin"

Westlake Village, California, UNITED STATES


WESTLAKE VILLAGE, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH), issued a release on Wednesday, April 29, with the headline "Photo Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drug." The company is updating this release to include videos, which accompany the release issued yesterday.

Videos accompanying this release are available at:

http://www.globenewswire.com/newsroom/prs/?pkgid=32574

http://www.globenewswire.com/newsroom/prs/?pkgid=32575

http://www.globenewswire.com/newsroom/prs/?pkgid=32576


        

Contact Data